Literature DB >> 31882495

A Clinicopathological Analysis of S100A14 Expression in Colorectal Cancer.

Angela Diamantopoulou1, Dimitrios Mantas1, Ioannis D Kostakis2, George Agrogiannis3, Zoe Garoufalia1, Nikolaos Kavantzas3, Gregory Kouraklis1.   

Abstract

BACKGROUND/AIM: The calcium-binding protein S100A14 is involved in processes related to tumorigenesis and tumor propagation, such as proliferation, apoptosis, motility and invasiveness. Our aim was to investigate its role in colorectal cancer. PATIENTS AND METHODS: One hundred and seven patients (65 men and 42 women) were included in this study. They had been diagnosed with colorectal cancer and undergone complete resection of their primary tumor. Tissue samples from archival blocks of their normal and malignant colorectal tissues were used for immunohistochemical assessment of S100A14 expression. S100A14 levels were evaluated using image analysis and associated with various clinicopathological parameters and prognosis.
RESULTS: S100A14 expression was reduced in malignant tissues when compared to normal intestinal mucosa in cases of T3-T4 tumors (p=0.017). Moreover, as far as S100A14 levels in malignant tissues are concerned, they were lower in T3-T4 tumors (p=0.001), N2 disease (p=0.034) and M1 disease (p=0.019). Finally, very high S100A14 production (>75th percentile) was associated with shorter disease-specific (HR=3.584, p=0.045) and relapse-free survival (HR=4.527, p=0.007) in multivariate survival analysis.
CONCLUSION: S100A14 expression is decreased in advanced colorectal cancer. However, cases with very high S100A14 levels have a worse survival. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  S100A14; colorectal cancer; immunohistochemistry; large intestine

Mesh:

Substances:

Year:  2020        PMID: 31882495      PMCID: PMC6984099          DOI: 10.21873/invivo.11777

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  33 in total

1.  S100A14 regulates the invasive potential of oral squamous cell carcinoma derived cell-lines in vitro by modulating expression of matrix metalloproteinases, MMP1 and MMP9.

Authors:  Dipak Sapkota; Ove Bruland; Daniela Elena Costea; Hallvard Haugen; Endre N Vasstrand; Salah O Ibrahim
Journal:  Eur J Cancer       Date:  2010-11-10       Impact factor: 9.162

Review 2.  Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Demetrios Moris; Christos Damaskos; Eleftherios Spartalis; Alexandros Papalampros; Spyridon Vernadakis; Dimitrios Dimitroulis; John Griniatsos; Evangelos Felekouras; Nikolaos Nikiteas
Journal:  Anticancer Res       Date:  2017-05       Impact factor: 2.480

3.  S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.

Authors:  Sidse Ehmsen; Lea Tykgaard Hansen; Martin Bak; Charlotte Brasch-Andersen; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Int J Cancer       Date:  2015-05-21       Impact factor: 7.396

Review 4.  Certainty of S100 from Physiology to Pathology.

Authors:  Puneeth Horatti Kuberappa; Bhavana Shivanand Bagalad; Anuradha Ananthaneni; Md Asif Kiresur; Guduru Vijay Srinivas
Journal:  J Clin Diagn Res       Date:  2016-06-01

5.  S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE).

Authors:  Qing'e Jin; Hongyan Chen; Aiping Luo; Fang Ding; Zhihua Liu
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

6.  Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion.

Authors:  Mizuko Tanaka; Naoki Ichikawa-Tomikawa; Namiko Shishito; Keisuke Nishiura; Tomiko Miura; Ayumi Hozumi; Hideki Chiba; Sayaka Yoshida; Tohru Ohtake; Takashi Sugino
Journal:  BMC Cancer       Date:  2015-02-13       Impact factor: 4.430

7.  SOX2 suppresses the mobility of urothelial carcinoma by promoting the expression of S100A14.

Authors:  Moon-Sing Lee; Wan-Ting Hsu; Yi-Fang Deng; Ching-Wei Lin; Erh-Ying Weng; Hsin-Ping Chang; Shu-Fen Wu; Chin Li
Journal:  Biochem Biophys Rep       Date:  2016-06-25

8.  The role of S100A14 in epithelial ovarian tumors.

Authors:  Hanbyoul Cho; Ha-Yeon Shin; Sunghoon Kim; Jane Seon-Young Kim; Joon-Yong Chung; Eun Joo Chung; Kyung-Hee Chun; Stephen M Hewitt; Jae-Hoon Kim
Journal:  Oncotarget       Date:  2014-06-15

Review 9.  Role of S100 Proteins in Colorectal Carcinogenesis.

Authors:  Paula Moravkova; Darina Kohoutova; Stanislav Rejchrt; Jiri Cyrany; Jan Bures
Journal:  Gastroenterol Res Pract       Date:  2016-01-06       Impact factor: 2.260

10.  Calcium-binding protein S100A14 induces differentiation and suppresses metastasis in gastric cancer.

Authors:  Min Zhu; Hongyi Wang; Jiantao Cui; Wenmei Li; Guo An; Yuanming Pan; Qingying Zhang; Rui Xing; Youyong Lu
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

View more
  2 in total

1.  S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway.

Authors:  Shaoqin Jiang; Yaru Zhu; Zhenlin Chen; Zhangcheng Huang; Bingqiao Liu; Yue Xu; Zhihao Li; Zequn Lin; Mengqiang Li
Journal:  Hum Cell       Date:  2021-04-23       Impact factor: 4.174

2.  S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3-mediated programmed death-ligand 1 expression in colorectal cancer.

Authors:  Hye-Young Min; Jaebeom Cho; Jeong Yeon Sim; Hye-Jin Boo; Ji-Sun Lee; Seon-Boon Lee; Young-Jin Lee; Sung Joo Kim; Kyu-Pyo Kim; In-Ja Park; Seung-Mo Hong; Xue-Li Zhang; Zhi-Gang Zhang; Rang-Woon Park; Ho-Young Lee
Journal:  Clin Transl Med       Date:  2022-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.